Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a drug that overcomes some of these barriers, marking cancer cells for destruction by the immune system.
“The immune system already has the potential to recognize mutated KRAS, but it usually can’t find it very well. When we put this marker on the protein, it becomes much easier for the immune system,” said UCSF chemist and Howard Hughes Medical Institute Investigator Kevan Shokat, Ph.D., who also helped lead the new work.
KRAS mutations are found in about one quarter of all tumors, making them one of the most common gene mutations in cancer. Mutated KRAS is also the target of sotorasib, which the Food and Drug Administration (FDA) has given preliminary approval for use in lung cancer, and the two approaches may eventually work well in combination.
“It’s exciting to have a new strategy leveraging the immune system that we can combine with targeted KRAS drugs,” said Charles Craik, Ph.D., a lead study author and professor of pharmaceutical chemistry at UCSF. “We suspect that this could lead to deeper and longer responses for cancer patients.”
Turning cancer markers inside out
The immune system typically recognizes foreign cells because of unusual proteins that jut out of their surfaces. But when it comes to cancer cells, there are few unique proteins found on their outsides. Instead, most proteins that differentiate tumor cells from healthy cells are inside the cells, where the immune system can’t detect them.
For many years, KRAS—despite how common it is in cancers—was considered undruggable. The mutated version of KRAS, which drives the growth of tumor cells, operates inside cells, often has only one small change that differentiates it from normal KRAS, and didn’t have a clear spot on its structure for a drug to bind. But over recent decades, Shokat carried out detailed analyses of the protein and discovered a hidden pocket in mutated KRAS that a drug could block. His work contributed to the development and approval of sotorasib.
In the new work, the team shows that when ARS1620—a targeted KRAS drug similar to sotorasib—binds to mutated KRAS, it doesn’t just block KRAS from effecting tumor growth. It also coaxes the cell to recognize the ARS1620-KRAS complex as a foreign molecule.
“This mutated protein is usually flying under the radar because it’s so similar to the healthy protein,” says Craik. “But when you attach this drug to it, it gets spotted right away.”
That means the cell processes the protein and moves it to its surface, as a signal to the immune system. The KRAS that was once hidden inside is now displayed as an “eat me” flag on the outside of the tumor cells.
A promising immunotherapy
With the shift of mutated KRAS from the inside to the outside of cells, the UCSF team was next able to screen a library of billions of human antibodies to identify those that could now recognize this KRAS flag. The researchers showed with studies on both isolated protein and human cells that the most promising antibody they had identified could bind tightly to the drug ARS1620 as well as the ARS1620-KRAS complex.
Then, the group engineered an immunotherapy around that antibody, coaxing the immune system‘s T cells to recognize the KRAS flag and target cells for destruction. They found that the new immunotherapy could kill tumor cells that had the mutated KRAS and were treated with ARS1620, including those that had already developed resistance to ARS1620.
“What we’ve shown here is proof of principle that a cell resistant to current drugs can be killed by our strategy,” says Shokat.
More work is needed in animals and humans before the treatment could be used clinically.
The researchers say that the new approach could pave the way not only for combination treatments in cancers with KRAS mutations, but also other similar pairings of targeted drugs with immunotherapies.
“This is a platform technology,” says Craik. “We’d like to go after other targets that might also move molecules to the cell surface and make them amenable to immunotherapy.”
In addition to Shokat and Craik, Ziyang Zhang, Peter J. Rohweder, Chayanid Ongpipattanakul, Koli Basu, Markus F. Bohn, Eli J. Dugan, Veronica Steri and Byron Hann of UCSF were also authors on the paper.
News
Scientists Use Exotic DNA To Help Create “Climate-Proof” Crops
The incorporation of exotic DNA from wild relatives into wheat results in a remarkable yield increase of up to 50%, even in hot weather, surpassing elite lines without these genes. Amid a year of [...]
Australia becomes first country to recognise psychedelics as medicines
Australia has become the first country to recognise psychedelics as medicines, after the Therapeutic Goods Administration took researchers by surprise and approved the psychedelic substances in magic mushrooms and MDMA for use by people [...]
Silver nanoparticles show promise in fighting antibiotic-resistant bacteria
In a new study, scientists with the University of Florida have found that a combination of silver nanoparticles and antibiotics is effective against antibiotic-resistant bacteria. The researchers hope to turn this discovery into viable [...]
Combating severe cancer with a new drug delivery system
Peritoneal cancer is difficult to treat and has a poor survival prognosis. But a new and effective nanomedicine delivery system is offering some hope. The company is called NaDeNo and is well underway with [...]
New Research Shows How Ketamine Acts As “Switch” in the Brain
According to a new study by researchers at Penn Medicine, ketamine, which is well-known as an anesthetic and is becoming increasingly popular as an antidepressant, dramatically reorganizes activity in the brain, almost as if [...]
Supercharged T Cells: A New Way To Kill Pancreatic Cancer With Minimal Side Effects
A new immunotherapy releases cancer-killing cytokines only within the tumor. Researchers at the University of California San Francisco (UCSF) have developed a new T cell-based immunotherapy that selectively targets cancer cells, producing a powerful anti-cancer cytokine [...]
AI has designed bacteria-killing proteins from scratch – and they work
An AI was tasked with creating proteins with anti-microbial properties. Researchers then created a subset of the proteins and found some did the job. An AI has designed anti-microbial proteins that were then tested [...]
Using nanoparticles, researchers can identify and deliver synergistic combinations of cancer drugs
Treating cancer with combinations of drugs can be more effective than using a single drug. However, figuring out the optimal combination of drugs, and making sure that all of the drugs reach the right [...]
Humanity May Reach Singularity Within Just 7 Years, Trend Shows
By one unique metric, we could approach technological singularity by the end of this decade, if not sooner. A translation company developed a metric, Time to Edit (TTE), to calculate the time it takes for professional [...]
HYPER (Highly Interactive Particle Relics) – A New Model for Dark Matter
Phase transition in early universe changes strength of interaction between dark and normal matter. Dark matter remains one of the greatest mysteries of modern physics. It is clear that it must exist, because without [...]
New Nanoparticles Deliver Therapy Brain-Wide and Edit Alzheimer’s Gene
Summary: Researchers have developed a new family of nano-scale capsules capable of carrying CRISPR gene editing tools to different organs of the body before harmlessly dissolving. The capsules were able to enter the brains of [...]
Cancer’s Secret Weapon? Enzyme That Protects Against Viruses May Fuel Tumor Evolution
An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a study led by investigators at Weill Cornell Medicine. The [...]
Scientists Uncover Japanese Fruit Juice That May Help Prevent Lung Cancer
Using a mouse model, Japanese researchers unleash the likely mechanism of action of Actinidia arguta (sarunashi) juice on lung cancer development. Lung cancer is a leading cause of death in Japan and across the [...]
In-place manufacturing method improves gas sensor capabilities, production time
When used as wearable medical devices, stretchy, flexible gas sensors can identify health conditions or issues by detecting oxygen or carbon dioxide levels in the breath or sweat. They also are useful for monitoring [...]
In the core of the cell: New insights into the utilization of nanotechnology-based drugs
Novel drugs, such as vaccines against covid-19, among others, are based on drug transport using nanoparticles. Whether this drug transport is negatively influenced by an accumulation of blood proteins on the nanoparticle’s surface was [...]
The costly lesson from COVID: why elimination should be the default global strategy for future pandemics
Imagine it is 2030. Doctors in a regional hospital in country X note an expanding cluster of individuals with severe respiratory disease. Rapid whole-genome sequencing identifies the disease-causing agent as a novel coronavirus. Epidemiological [...]
